China's best-known hemorrhoid-ointment brand, now also selling musk-based skincare and other OTC health products.
China's best-known hemorrhoid-ointment brand, now also selling musk-based skincare and other OTC health products.
Depends on one product family: the musk hemorrhoid ointment and suppositories, sold mostly through pharmacy chains and online, dominate what the company earns. Skincare and other OTC health products, many using the same musk ingredient, are its route to broaden that base.
In one line: A single-brand Chinese Preparation H maker.
Moat: narrow (brand). Decades-old, near-household-name OTC brand with strong pharmacy shelf presence.
Headquarters: Wuhan, China · Employees: 2,544
Size Mayinglong Pharmaceutical (600993.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.70B, the 1355th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥25.97 on 18 Nov 2026.
Performance Over six months the shares gained 1.8%, against -3.0% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 6.6% over the last twelve months (peer median +13.8%); the operating margin is 16.7% (peer median 12.0%).
Valuation It trades at 17.0× forward earnings against a peer median of 22.0× (4th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.8 points above its cost of capital (5.6% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.99B | CN¥3.84B | CN¥3.70B | CN¥3.11B | CN¥3.51B |
| Revenue growth | — | +4% | +19% | -11% | — |
| Gross profit | CN¥1.90B | CN¥1.83B | CN¥1.67B | CN¥1.25B | CN¥1.43B |
| EBITDA | n/a | CN¥745M | CN¥675M | CN¥471M | CN¥577M |
| Net income | CN¥595M | CN¥581M | CN¥528M | CN¥443M | CN¥479M |
| Free cash flow | CN¥691M | CN¥481M | CN¥294M | CN¥373M | CN¥297M |
| Capital expenditure | CN¥106M | CN¥119M | CN¥204M | CN¥248M | CN¥75.0M |
| Total debt | CN¥246M | CN¥252M | CN¥398M | CN¥380M | CN¥801M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical 600993.SS | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600993.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.2% | -2.8% | 5th highest of 21 |
| 6-month return | +1.8% | -3.0% | 10th highest of 20 |
| Distance from 52-week high | -13.9% | -36.7% | 5th highest of 21 |
| Revenue growth (TTM) | +6.6% | +13.8% | 9th lowest of 20 |
| Operating margin | 16.7% | 12.0% | 7th highest of 20 |
| Forward P/E | 17.0× | 22.0× | 4th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -3.5% | 19.5% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +6.8% | +9.6% | 6th lowest of 17 |
| Hurdle (Req g minus delivered) | -10.2 pp | +4.8 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +15.8 pp | -2.7 pp | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |